On September 10th, AVEO Oncology (AVEO) publicized their analysis of overall survival “OS” in FOTIVDA’s TIVO-3 trial. This trial was a Phase III study comparing FOTIVDA (tivozanib) to Bayer’s (OTCPK:BAYRY) Nexavar (sorafenib) in patients with highly refractory metastatic renal cell carcinoma “RCC”. The company reported that they finally recorded a sub-1.00 OS hazard ratio “HR”. Prior to this analysis, FOTIVDA's HR was greater than 1.0, which shows that subjects receiving FOTIVDA are at greater risk of death than subjects who are getting other treatments. FOTIVDA’s HR has been the subject of